Company Overview

We develop transformative medicines and technologies by building agile, focused companies called Vants.

Why We're Here

Roivant was founded in 2014 with the aim to improve the lives of patients by accelerating the development and commercialization of medicines that matter.

01

Roivant builds nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies

Our Vants have conducted 10 positive Phase 3 trials since 2019, and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults

02

1 Successful Commercial Launch

In 2022, we launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults

03

Diverse leadership and employee base

We have worked to ensure an open, diverse, and inclusive culture, while building a leadership team, board of directors and broader employee base that reflects these values.

Our vant creation Process:

Our vant creation Process
Cellular Background

6

FDA approvals


We have a diverse pipeline of investigational drugs across our family of companies.


For Investors
For Investors

Learn more about our work

Sign up for our latest announcements and upcoming presentations

Pipeline
Pipeline

Advancing medicines that matter

View our broad and differentiated pipeline of investigational drugs.